Synbiotic Health Announces the Expansion of their R&D and Commercial Capabilities with the Acquisition of a New Facility in Madison, Wisconsin
Lincoln, Nebraska | November 1, 2022: Synbiotic Health, a market leader in the discovery, development, and commercialization of probiotic ingredients, announced that the company has expanded its R&D and commercial capabilities with the acquisition of a 43,000 sf facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialization of advanced probiotic ingredients for improved health.
The Madison facility, which is scheduled to come online in early 2023, will focus on scale-up and development of efficient commercial processes. It is designed to complement the company’s existing facilities in Lincoln, Nebraska, which are dedicated to the discovery of new probiotic strains. The Madison facility is being constructed specifically to support probiotics in a quality-focused, GMP environment that features very low humidity levels in all areas where probiotic ingredients will be found. New lab space, which will have the capacity to accommodate numerous scientists, will allow Synbiotic Health to quickly screen new probiotics for growth and stability, thus increasing the company’s ability to introduce new high quality strains to the market.
Tim Brummels, President and CEO of Synbiotic Health, stated “This expansion of our capabilities is strategically aligned with the company’s goals. It brings our legacy of expertise in Nebraska, which is focused on discovery, to the next level. We are investing in the next phase of microbiome health: post-discovery development and commercialization that will efficiently bring products to market.”
As evidence of the cutting-edge science the company is known for, Synbiotic Health was recently honored to be named the 2022 recipient of the Governor’s Bioscience Award, presented by Nebraska Governor Pete Ricketts. The Governor’s Bioscience Award is presented annually to an individual or company that has made significant contributions to Nebraska’s bioscience industry. The selection criteria range from conducting innovative research to product development to investment that grows the bioscience community in Nebraska.
In accepting the award, Mr. Brummels added, “We are proud to be able to take some of Nebraska’s leading academic science and turn it into innovative products that are unmatched in the global probiotics industry. We expect to deliver the same high level of scientific expertise at commercial scale from our new site in Madison.”
When fully operational in 2023, the Madison site is expected to employ a workforce of up to thirty-five employees, which will include technical, operations and administrative personnel. In addition to the R&D and commercial activities that will be operational at launch, the facility is expected to expand in the future with the addition of new services and capabilities that will provide added value to the dietary supplement market.
About Synbiotic Health
Synbiotic Health was founded in 2018 by four microbiome research scientists to develop targeted microbiome ingredients to support health. Based on over 10 years of research, Synbiotic Health will develop and commercialize Ecologically Advanced Probiotics® as well as rationally designed Synergistic Synbiotics®.
The foundation of Synbiotic Health’s research focuses on understanding the gut environment and its ecological framework: how probiotics and other microbiome-based ingredients interact with and influence the resident microbes in the gut. Synbiotic Health’s approach considers the entire ecosystem and the specific traits and functions necessary for microbiome-altering ingredients to perform and improve human health.
The Scientific Founder team includes Dr. Robert Hutkins and Dr. Andy Benson with the University of Nebraska-Lincoln’s Food for Health Center; Dr. Jens Walter with APC Microbiome Ireland, University College Cork; and Dr. Tom Burkey, an animal scientist with the University of Nebraska-Lincoln.
Synbiotic Health has commercialized its first two Ecologically Advanced® probiotics: the clinically studied iVS-1® and the laboratory researched iVE-15® . Further clinical studies to demonstrate the health benefits of these novel ingredients are currently underway, with additional future studies planned for 2023 and 2024.
For more information, visit synbiotichealth.com. To arrange a press interview, please contact email@example.com.